Opus Genetics IRD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $14.2M+29.1% | $10.99M-42.3% | $19.05M-52.2% | $39.85M— | ||
| —— | —— | —— | —— | ||
| $21.98M+20.7% | $18.22M+52.3% | $11.96M+64.5% | $7.27M-10.5% | ||
| $52.8M-27.7% | $73.07M+147% | $29.61M+36.9% | $21.62M-7.2% | ||
| -$38.6M+37.8% | -$62.07M-488% | -$10.56M-158% | $18.23M+180% | ||
| -271.9%+293pp | -564.7%-509pp | -55.5%-101pp | 45.7%— | ||
| $129K— | $0— | $0-100% | $9K+350% | ||
| $1.99M-55.5% | $4.47M+143% | $1.84M— | —— | ||
| -$49.59M+13.8% | -$57.53M-477% | -$9.97M-155% | $18.2M+132% | ||
| $0— | $0— | —— | $315K— | ||
| -$49.59M+13.8% | -$57.53M-476% | -$9.99M-156% | $17.89M+132% | ||
| -349.3%+174pp | -523.4%-471pp | -52.4%-97.3pp | 44.9%— | ||
| -$0.82+61.9% | -$2.15-348% | -$0.48-155% | $0.87+119% | ||
| -$38.55M+37.9% | -$62.06M-488% | -$10.56M-158% | $18.23M+180% | ||
| -271.5%+293pp | -564.6%-509pp | -55.4%-101pp | 45.7%— | ||
| -$38.6M+37.8% | -$62.07M-488% | -$10.56M-158% | $18.23M+180% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Opus Genetics's revenue?
- Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.
- Is Opus Genetics profitable?
- Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.
- What is Opus Genetics's earnings per share?
- Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.
- Where does Opus Genetics's income statement data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
